Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 1, 2010, Pages 11-20

  Au, Wai Ling ^a   Skinner, Michael ^a   Kanfer, Isadore ^a  

^a RHODES UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; DOVATE; UNCLASSIFIED DRUG; CLOBETASOL; GLUCOCORTICOID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; BIOEQUIVALENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREAM; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; OINTMENT; PILOT STUDY; SKIN BLANCHING ASSAY; SKIN TEST; TAPE STRIPPING METHOD; BIOAVAILABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FOOD AND DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SKIN; SKIN ABSORPTION; UNITED STATES; VALIDATION STUDY;

ADMINISTRATION, CUTANEOUS; ADULT; BIOLOGICAL AVAILABILITY; CLOBETASOL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PILOT PROJECTS; SKIN; SKIN ABSORPTION; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 77955496487     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3c01r     Document Type: Article

References (29)

1. V. P. Shah, G. L. Flynn, A. Yacobi, H. I. Maibach, C. Bon, N. M. Fleischer, T. J. Franz, S. A. Kaplan, J. Kawamoto, L. J. Lesko, J.-P. Marty, L. K. Pershing, H. Schaefer, J. A. Sequeira, S. P. Shrivastava, J. Wilkin, and R. L. Williams. Bioequivalence of topical dermatological dosage forms - methods of evaluation of bioequivalence. Pharm. Res., 15:167-171, 1998.
2. FDA. Guidance for industry: topical dermatological corticosteroids: in vivo bioequivalence. Center for Drug Evaluation, Food and Drug Administration, MD, USA 1995.
3. EMEA. Questions and answers on guideline: clinical investigations of corticosteroids intended for use on the skin. CHMP/EWP/21441/2006, European Medicines Agency, London, UK 2006.
4. FDA. Guidance of industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Center for Drug Evaluation, Food and Drug Administration, MD, USA 2000.
5. HC. Policy issues from the drugs directorate, submissions for generic topical drugs. Health Canada, Ottawa, Canada 1990.
6. MCC. Biostudies Guideline. Medicines Control Council, South Africa 2007.
7. A. W. McKenzie and R. B. Stoughton. Method for comparing percutaneous absorption of steroids. Arch. Dermatol., 86:608-610, 1962.
8. D. Dupuis, A. Rougier, R. Roguet, and C. Lotte. The measurement of the stratum corneum reservoir: a simple method to predict the influence of vehicles on in vivo percutaneous absorption. Brit. J. Dermatol., 115:233-238, 1986.
9. C. Puglia, P. Blasi, L. Rizza, A. Schoubben, F. Bonina, C. Rossi, and M. Ricci. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int. J. Pharm., 357:295-304, 2008.
10. J. C. Tsai, S. A. Chuang, M. Y. Hsu, and H. M. Sheu. Distribution of salicylic acid in human stratum corneum following topical application in vivo: a comparison of six different formulations. Int. J. Pharm., 188:145-153, 1999.
11. G. K. Menon, K. R. Feingold, and P. M. Elias. Lamellar body secretory response to barrier disruption. J. Invest. Dermatol., 98:279-289, 1992.
12. C. Herkenne, I. Alberti, A. Naik, Y. N. Kalia, F.-X. Mathy, V. Préat, and R. H. Guy. In vivo methods for the assessment of topical drug bioavailability. Pharm. Res., 25:87-103, 2008.
13. E. Benfeldt, S. H. Hansen, A. Vølund, T. Menné, and V. P. Shah. Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J. Invest. Dermatol., 127:170-178, 2007.
14. B. N'Dri-Stempfer, W. C. Navidi, R. H. Guy, and A. L. Bunge. Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm. Res., 25:1621-1630, 2008.
15. L. K. Pershing, J. L. Nelson, J. L. Corlett, S. P. Shrivastava, D. B. Hare, and V. P. Shah. Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J. Am. Acad. Dermatol., 48:740-751, 2003.
16. J. C. Tsai, C. L. Cheng, Y. F. Tsai, H. M. Sheu, and C. H. Chou. Evaluation of in vivo bioequivalence methodology for topical clobetasol 17-propionate based on pharmacodynamic modeling using chinese skin. J. Pharm. Sci., 93:207-217, 2004.
17. L. K. Pershing, L. D. Lambert, V. P. Shah, and S. Y. Lam. Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. Int. J. Pharm., 86:201-210, 1992.
18. L. K. Pershing, B. S. Silver, G. G. Krueger, V. P. Shah, and P. Skelley. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm. Res., 9:45-51, 1992.
19. Y. N. Kalia, I. Alberti, N. Sekkat, C. Curdy, A. Naik, and R. H. Guy. Normalization of stratum corneum barrier function and transepidermal water loss in vivo. Pharm. Res., 17:1148-1150, 2000.
20. L. M. Russell, S. Wiedersberg, and M. Begoña Delgado-Charro. The determination of stratum corneum thickness. An alternative approach. Eur. J. Pharm. Biopharm., 69:861-870, 2008.
21. W. L. Au, M. Skinner, and I. Kanfer, Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching. J. Pharm. Pharmaceut. Sci, 11:147-153, 2008.
22. N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet., 6:429-453, 1981.
23. E. Meyer, E. W. Smith, and J. M. Haigh. Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching. Brit. J. Dermatol., 127:379-381, 1992.
24. H. J. Weigmann, J. Lademann, R. von Pelchrzim, W. Sterry, T. Hagemeister, R. Molzahn, M. Schaefer, M. Lindscheid, H. Schaefer, and V. P. Shah. Bioavailability of clobetasol propionate - quantification of drug concentrations in the stratum corneum by dermatopharmacokinetics using tape stripping. Skin Pharmacol. Appl. Skin Physiol., 12:46-53, 1999.
25. FDA. Guidance for industry: bioanalytical method validation. Center for Drug Evaluation and Research, Food and Drug Administration, MD, USA, 2001.
26. R. N. O. Tettey-Amlalo, I. Kanfer, M. F. Skinner, E. Benfeldt, and R. K. Verbeeck. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur. J. Pharm. Sci., 36:219-225, 2009.
27. E. Diletti, D. Hauschke, and V. W. Steinijans. Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxic., 29:1-8, 1991.
28. D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokin. Biopharm., 15:657-680, 1987.
29. C. S. Locke. An exact confidence interval for unstransformed data for the ratio of two formulation means. J. Pharmacokin. Biopharm., 12:649-655, 1984.